Frontlight ResearchEarly access
CompletedNo phase
Exploratory Study on the Effect of SAT-001 on Choroidal Thickness in Pediatric Myopia Patients
Key facts
- Who runs it
- S-Alpha Therapeutics, Inc.
- Where
- South Korea2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 19 Aug 2024
- Ended
- 31 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SAT-001
- modified SAT-001
- Record updated
- 10 January 2025
Who can take part
- Age
- 4 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Children aged 4 to 12
- Meet the following refractive criteria by cycloplegic refraction; Spherical equivalent refractive error (SER): -0.75 to less than -6.00 D in both eyes; Astigmatism of 2.50 D or less in both eyes
- Best corrected visual acuity of 0.2 logMAR or better in each eye at the Screening Visit
- Gestational age of 38 weeks or more at birth, or birth weight of 2,500g or more
- Transparent ocular media
- Participants and their legal guardians who agree to participate in the clinical trial and are willing to provide signed informed consent after receiving and understanding the explanation of the trial description (participants under 6 years old may mark their agreement after receiving full information and understanding)
Who cannot take part
- History of multifocal lenses (e.g., progressive lenses), corneal refractive therapy lenses (Ortho-K, e.g., Dream lenses), rigid gas permeable (RGP) hard lenses, defocus incorporated multiple segments (DIMS) spectacle lenses (e.g., MyoSmart) within 30 days prior to Visit 2
- History of using myopia control agents (e.g., atropine) within 30 days prior to Visit 2
- Currently participating in another clinical trial or who have participated in another clinical trial within 3 months prior to screening (Visit 1)
- History of eye diseases such as manifest strabismus, intermittent strabismus, amblyopia, and nystagmus (excluding strabismus that maintains binocular vision)
- History of ocular surgery such as eyelid surgery, strabismus surgery, intraocular surgery, or refractive correction surgery (excluding simple double eyelid surgery)
- Ocular abnormalities in cornea, lens, central retina, iris, ciliary body, etc., or presence of malignant tumors in the orbital area
- Inappropriate at the discretion of the investigator due to potential ethical concerns or the possibility of affecting the clinical trial results
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to exploratively compare and evaluate the structural changes in the eye (specifically changes in choroidal thickness) pre- and post-treatment of the investigational medical devices ('SAT-001' and 'modified SAT-001') in pediatric myopia patients, and the differences in their effects on the eye.
The 2 groups in the trial
- SAT-001 Treatment GroupTreatment being tested
Using SAT-001 for 30 minutes
Treatment: SAT-001
- Modified SAT-001 Treatment GroupExisting treatment, for comparison
using modified SAT-001, which excludes rest session from SAT-001, for 15 minutes
Treatment: modified SAT-001
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Open-label, Parallel-group, Exploratory Clinical Trial to Evaluate the Effect of the Software as a Medical Device (SaMD) SAT-001 on the Changes in Choroidal Thickness in Pediatric Myopia Patients
- Record updated
- 10 January 2025